Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
Andrew X ZhuRyan David NippRichard S FinnPeter R GalleJosep M LlovetJean-Frederic BlancTakuji OkusakaIan ChauDavid CellaAllicia GirvanJonathon GableLee BowmanChunxiao WangYanzhi HsuPaolo B AbadaMasatoshi KudoPublished in: ESMO open (2021)
NCT01140347; NCT02435433, NCT02435433.